FDA Updates SMA Treatment Dosing A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing. By Kathryn Wighton March 30, 2026 2 min Conexiant Share Summary Takeaways Listen Insight Report Clinical Scorecard Quiz Poll Top Institutions Top Thought Leaders
